Printer Friendly
The Free Library
19,607,053 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

ESTECH Signs Distribution Agreement with Neoprobe; ESTECH Initiates U.S. Distribution of Quantix Blood Flow Devices That Help Cardiac Surgeons Improve Patient Outcomes.


SAN FRANCISCO -- At the ISMICS ISMICS International Society for Minimally Invasive Cardiothoracic Surgery  (International Society For Minimally Invasive Cardiothoracic Surgery) 9th Annual Scientific Meeting, ESTECH, Inc. of San Ramon, CA, announced it has entered into a U.S. Distribution Agreement with Neoprobe Corporation (OTCBB OTCBB

See OTC Bulletin Board (OTCBB).
: NEOP NEOP Neoprobe Corporation (stock symbol)
NEOP Near Earth Object Program
NEOP New England Order of Protection
NEOP Nuclear Explosive Operating Procedure
) for the Cardiosconix Quantix/OR blood flow measurement system. The Quantix/OR is designed to provide surgeons with quantitative hemodynamic he·mo·dy·nam·ics  
n. (used with a sing. verb)
The study of the forces involved in the circulation of blood.



he
 information in coronary artery bypass graft coronary artery bypass graft
n. Abbr. CABG
A surgical procedure in which a section of vein or other conduit is grafted between the aorta and a coronary artery below the region of an obstruction in that artery.
 (CABG CABG coronary artery bypass graft.

CABG
abbr.
coronary artery bypass graft


CABG Coronary artery bypass graft, see there
) and carotid endarterectomy procedures.

"This technology represents our continuing goal of providing cardiac surgeons with innovative new technologies for improving patient outcomes when undergoing cardiac surgery procedures", said Ray Bertolero, ESTECH Vice President and co-founder. "The Quantix/OR system compliments our current offerings for cardiovascular surgery in the U.S. market while helping to make cardiac procedures more effective."

"The ESTECH agreement provides us with a proven national marketing organization and validates our belief in the blood flow measurement market," said David Bupp, President of Neoprobe. "By joining a leader in servicing the CABG marketplace, the Quantix/OR system will be better positioned to achieve broader market penetration. The strength of ESTECH's product offering will allow us to establish an important presence in the key market for our blood flow products."

About ESTECH

Headquartered in San Ramon, CA, ESTECH offers tools for least invasive techniques and traditional approaches to the procedures that cardiac surgeons do every day--coronary artery bypass, valve surgery, atrial ablation and surgical treatment of congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. .

About Neoprobe

Neoprobe develops and provides innovative surgical and diagnostic products that enhance patient care by meeting the critical decision making needs of healthcare professionals. Neoprobe's products are available throughout the world and are supported by a world-wide servicing capability.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jun 10, 2006
Words:274
Previous Article:Sports Series USB Flash Drives from Pretec; Novel yet Practical Mobile Storage.
Next Article:Newly Released Phase III Studies for JANUVIA(TM), Merck's Investigational Once-Daily Medicine for Type 2 Diabetes, Showed Significantly Reduced Blood...
Topics:



Related Articles
Neoprobe Releases Text of Letter to Stockholders.
Neoprobe Announces First Quarter Results; First Quarter Device Sales Increase 20% Over Prior Year; Business Update Provided and Conference Call...
Neoprobe Announces Second Quarter Results; Second Quarter Device Sales Increase 26% - Business Update Provided and Conference Call Scheduled.
Neoprobe and ESTECH Announce Distribution Agreement; ESTECH to Distribute Quantix Blood Flow Devices in U.S.
Neoprobe Announces Results of Annual Meeting; Company's CEO Provides Business Update.
Neoprobe Initiates Lymphoseek Phase 2 Clinical Study.
Neoprobe Announces Second Quarter Results; Business Update Provided and Conference Call Scheduled.
ESTECH Signs Expanded Distribution Agreement With Neoprobe; ESTECH to Distribute Quantix Blood Flow Devices in Europe and U.S.
Neoprobe Announces Third Quarter Results.
Neoprobe Secures $6 Million Commitment from Fusion Capital.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles